Two dosing options provide flexibility to meet the changing HAE needs of patients

Total doses per month for adult and adolescent patients ≥12 years of age

Q2W DOSING
TAKHZYRO1*

2

SUBCUTANEOUS INJECTIONS
VIA PREFILLED SYRINGE

one 300 mg/2mL injection every 2 weeks

OR

Q4W DOSING
TAKHZYRO1*

1

SUBCUTANEOUS INJECTION
VIA PREFILLED SYRINGE

one 300 mg/2mL injection every 4 weeks if well controlled (eg, attack free) for 6 months

Style
section-no-top-margin, section-no-bottom-margin, section-no-top-padding, section-no-bottom-padding, section-no-left-padding, section-no-right-padding, section-dosing-flex-tak

C1 ESTERASE INHIBITOR (HUMAN)

7

INTRAVENOUS INFUSIONS

1000 IU every 3 or 4 days

OR

SUBCUTANEOUS INJECTIONS

one injection twice weekly; every 3 or 4 days

ORAL PLASMA KALLIKREIN INHIBITOR

28

CAPSULES

one 150 mg capsule daily

This presentation is not intended to compare the relative safety or efficacy of these treatments. Please refer to each product's full Prescribing Information.

One month is defined as 28 days.
*The recommended starting dosage in adult and pediatric patients 12 years of age and older is 300 mg every 2 weeks.
A dosing interval of 300 mg every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1

Style
section-no-top-margin, section-no-bottom-margin, section-no-top-padding, section-no-left-padding, section-no-right-padding, section-dosing-flex-plasma

Two dosing options based on patients’ age and changing needs

Total doses per month for pediatric patients

AGES: 2 TO <6 YEARS

TAKHZYRO1
C1 ESTERASE INHIBITOR (HUMAN)
ORAL PLASMA KALLIKREIN INHIBITOR

1

SUBCUTANEOUS INJECTION
one 150 mg/1 mL injection every 4 weeks1†

No approved options
No approved options

AGES: 6 TO <12 YEARS

TAKHZYRO1
C1 ESTERASE INHIBITOR (HUMAN)
ORAL PLASMA KALLIKREIN INHIBITOR

2

SUBCUTANEOUS INJECTIONS
one 150 mg/1 mL injection every 2 weeks1‡

OR

1

SUBCUTANEOUS INJECTIONS
one 150 mg/1 mL injection via prefilled syringe every 4 weeks if well controlled (eg, attack free) for 6 months1‡

7

INTRAVENOUS INFUSIONS
1000 IU every 3 or 4 days

OR

SUBCUTANEOUS INJECTIONS
one injection twice weekly; every 3 or 4 days

No approved options

This presentation is not intended to compare the relative safety or efficacy of these treatments. Please refer to each product's full Prescribing Information.

TAKHZYRO is the only approved HAE preventive treatment indicated for pediatric patients 2 to <6 years of age.

One month is defined as 28 days.
*The recommended dosage in pediatric patients 2 to less than 6 years of age is 150 mg administered subcutaneously every 4 weeks.
†The recommended starting dosage in pediatric patients 6 to less than 12 years of age is 150 mg administered subcutaneously every 2 weeks. A dosing interval of 150 mg every 4 weeks may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1

Style
section-no-top-margin, section-no-bottom-margin, section-no-top-padding, section-no-bottom-padding, section-no-left-padding, section-no-right-padding, section-dosing-options